Home Previous Slide◀︎ Next Slide▶︎ We act with care to create value in the lives of the people we serve We always strive to find new ways to deliver solutions to people living with severe diseases Everyone deserves to live the best life that they can Current Slide Current Slide Current Slide
At UCB, we believe that everyone deserves to live the best life that they can. That’s why - as a global biopharmaceutical leader - we’re focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. Discover more about us UCBCares® UCBCares® is a personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine Contact us here A home for innovation Innovation is a key driver of progress in every aspect of human life including advancing healthcare. Find out more Learn more Empowering women of childbearing age UCB net-zero targets validated by the Science Based Targets initiative Discover the Unbearable Home UCB Stories & Newsroom Story Confronting the challenges of Prolonged Seizures Read More Story 6 Nov 2025 How FASTRAX is transforming patient care and proving that innovation can scale Read More Story 30 Oct 2025 Bridging the communication gap in Myasthenia Gravis: insights from the ENGAGE program Read More Press release 6 Nov 2025 UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation Read More Press release 3 Nov 2025 U.S. FDA approves KYGEVVI[®] (doxecitine and doxribtimine), the first and only treatment for adults... Read More “Every breakthrough we achieve brings us closer to a world where patients can live better, healthier lives.” Sustainability Sustainability is at the heart of everything we do at UCB, guiding our decisions to positively impact society, support communities, and protect the planet for future generations. Learn more UCB ventures UCB Ventures invests in pioneering companies and technologies that have the potential to transform the lives of people living with severe diseases. Learn more Choose a Country Global Site – English Australia – English België – Engels Belgique – Anglais Brasil – Português България – Български Canada – English Canada – Français 中国 – 中文 Česká Republika – Angličtina Danmark – Engelsk Deutschland – Deutsch France – Français España – Español Ελλάδα – Ελληνικά India – English Ireland – English Italia – Inglese 日本 – 日本語 한국 – 한국어 Luxembourg – Anglais Luxemburg – Engels Magyarország – Angol México & Latinoamérica – Español Nederland – Engels New Zealand – English Norge – Engelsk Österreich – Deutsch Polska – Polski Portugal – español y portugués România – Engleză Россия – Русский Slovensko – Anglický Suomi – Englanti Sverige – Engelska Schweiz – Deutsch Suisse – Français Türkiye – Türkçe Україна – Англійська United Kingdom – English U.S.A. – English ×
Story 6 Nov 2025 How FASTRAX is transforming patient care and proving that innovation can scale Read More
Story 30 Oct 2025 Bridging the communication gap in Myasthenia Gravis: insights from the ENGAGE program Read More
Press release 6 Nov 2025 UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation Read More
Press release 3 Nov 2025 U.S. FDA approves KYGEVVI[®] (doxecitine and doxribtimine), the first and only treatment for adults... Read More